Travere Therapeutics, Inc. (TVTX)
Nasdaq: TVTX · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2008
Who owns Travere Therapeutics, Inc.
As filed with the SECHolders of 5% or more
5
Janus Henderson Group PLC holds 11.9% of Common Stock, as its SCHEDULE 13G/A filed Nov 14, 2025 says.
Directors and officers
16
report now, of 24 people on the record since 2013. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Janus Henderson Group PLC
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock · 12.8% in Aug 7, 2025
Fmr LLC
SCHEDULE 13G/A · filed Aug 6, 2026 · COMMON STOCK · 11.7% in Jan 8, 2026
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 17, 2025 · Common Stock · 9.4% in Feb 5, 2025
Bank of America Corporation
SCHEDULE 13G · filed Aug 12, 2026 · Common Stock
Vanguard Capital Management
SCHEDULE 13G · filed Apr 30, 2026 · Common Stock
Perceptive Advisors LLC
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.5% in Oct 14, 2025
State Street Corporation
SCHEDULE 13G · filed Aug 7, 2026 · COMMON STOCK · reported falling below 5%, from 5.3% in Feb 9, 2026
Rock Springs Capital Management LP
SCHEDULE 13G/A · filed May 15, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.72% in Feb 14, 2025
Woodline Partners LP
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%
Armistice Capital, LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.27% in May 15, 2026
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%, from 6.74% in Jul 29, 2025
Macquarie Group Limited
SCHEDULE 13G/A · filed Feb 13, 2026 · Common Shares · reported falling below 5%, from 5.41% in May 15, 2025
What TVTX reports owning in othersstakes of 5% or more, and other ties
Travere Therapeutics, Inc. reports no stake in another company in the record.
Insider tradesForm 4
124sales
0purchases
116sales on a scheduled plan
11people selling
$117Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 19, 2025 to Oct 19, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 19, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window11 of 24 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Dube Eric M | CHIEF EXECUTIVE OFFICER | 24 | $54.5M | 24 | 0 | $0 |
| Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | 13 | $19.0M | 10 | 0 | $0 |
| Rote William E. | Chief Research Officer | 10 | $16.4M | 10 | 0 | $0 |
| Reed Elizabeth E | Chief Legal Officer and GC | 19 | $7.0M | 18 | 0 | $0 |
| Inrig Jula | EVP, Head of R&D & CMO | 15 | $5.2M | 14 | 0 | $0 |
| Cline Christopher R. | CHIEF FINANCIAL OFFICER | 15 | $4.6M | 13 | 0 | $0 |
| Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | 8 | $4.2M | 7 | 0 | $0 |
| Baynes Roy D. | director | 6 | $2.5M | 6 | 0 | $0 |
| Meckler Jeffrey A | director | 5 | $1.7M | 5 | 0 | $0 |
| Coughlin Timothy P | director | 3 | $1.3M | 3 | 0 | $0 |
| Lyons Gary A | director | 6 | $1.0M | 6 | 0 | $0 |